SG10202110594UA - Methods of treating tumor - Google Patents

Methods of treating tumor

Info

Publication number
SG10202110594UA
SG10202110594UA SG10202110594UA SG10202110594UA SG10202110594UA SG 10202110594U A SG10202110594U A SG 10202110594UA SG 10202110594U A SG10202110594U A SG 10202110594UA SG 10202110594U A SG10202110594U A SG 10202110594UA SG 10202110594U A SG10202110594U A SG 10202110594UA
Authority
SG
Singapore
Prior art keywords
methods
treating tumor
tumor
treating
Prior art date
Application number
SG10202110594UA
Inventor
Prabhu Seshaiyer Bhagavatheeswaran
Nicholas Allan John Botwood
Han Chang
Yali Fu
William J Geese
George A Green
Diane Healey
Sabine Maier
Faith E Nathan
Abderrahim Oukessou
Giovanni Selvaggi
Joseph Daniel Szustakowski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG10202110594UA publication Critical patent/SG10202110594UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
SG10202110594UA 2017-03-31 2018-03-30 Methods of treating tumor SG10202110594UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479817P 2017-03-31 2017-03-31
US201762582146P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
SG10202110594UA true SG10202110594UA (en) 2021-11-29

Family

ID=62067782

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908396P SG11201908396PA (en) 2017-03-31 2018-03-30 Methods of treating tumor
SG10202110594UA SG10202110594UA (en) 2017-03-31 2018-03-30 Methods of treating tumor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201908396P SG11201908396PA (en) 2017-03-31 2018-03-30 Methods of treating tumor

Country Status (13)

Country Link
US (2) US20210101980A1 (en)
EP (1) EP3601355A1 (en)
JP (1) JP7458188B2 (en)
KR (1) KR20190133213A (en)
CN (1) CN110494450A (en)
AU (1) AU2018243754A1 (en)
BR (1) BR112019019795A2 (en)
CA (1) CA3058175A1 (en)
IL (1) IL269026A (en)
MA (1) MA50056A (en)
MX (1) MX2019010958A (en)
SG (2) SG11201908396PA (en)
WO (1) WO2018183928A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7014706B2 (en) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド Anti-PD-1 antibody, activating anti-PD-1 antibody, and how to use it
RU2729830C2 (en) 2015-08-11 2020-08-12 Уси Байолоджикс (Кайман) Инк. Novel anti-pd-1 antibodies
KR20200064132A (en) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
CA3093407A1 (en) * 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019191676A1 (en) * 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
EP3857555A4 (en) * 2018-10-17 2022-12-21 Tempus Labs Data based cancer research and treatment systems and methods
KR20210081384A (en) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
JP2022513068A (en) * 2018-11-15 2022-02-07 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド How to Improve Prediction of Responses in Cancer Patients Treated with Immunotherapy
WO2020121226A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer
EP3899951A1 (en) 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
GB201904555D0 (en) * 2019-04-01 2019-05-15 Univ Manchester Biomarkers and uses thereof
CN110229894B (en) * 2019-05-21 2020-09-08 武汉大学 Gene combination and application thereof in preparation of reagent for predicting prognosis of patient receiving immune checkpoint inhibitor treatment
EP3982954A4 (en) * 2019-06-14 2024-01-03 Univ Columbia Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
US11752197B2 (en) 2019-08-12 2023-09-12 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
JP2022551921A (en) * 2019-10-09 2022-12-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル DNA Copy Number Abnormalities (CNAs) for Determining Cancer Phenotypes
CN110927389B (en) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 Cancer biomarker and application
CN111269979A (en) * 2020-02-06 2020-06-12 至本医疗科技（上海）有限公司 Application of ARID1B gene variation in prediction of sensitivity of lung adenocarcinoma patient to immune checkpoint inhibitor therapy
CN110923329B (en) * 2020-02-06 2020-05-12 至本医疗科技（上海）有限公司 Application of FGFR4 point mutation in prediction of sensitivity of non-small cell lung cancer patient to immune checkpoint inhibitor therapy
CN115667552A (en) * 2020-05-21 2023-01-31 阿斯利康(瑞典)有限公司 Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial cancer
TWI788188B (en) * 2020-06-09 2022-12-21 南韓商阿特根公司 Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drug
CN112143810B (en) * 2020-09-29 2023-11-21 南方医科大学中西医结合医院 Gene markers for predicting cancer immunotherapy effect and application thereof
WO2022135402A1 (en) * 2020-12-24 2022-06-30 信达生物制药(苏州)有限公司 Use of pd-l1 and/or mhc-2 biomarker in prediction of therapeutic efficacy in lung cancer patients
KR102371762B1 (en) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Use for regulating cell differentiation and apoptosis by BRCA1 mediated NSD2 ubiquitination
CN113005146A (en) * 2021-03-10 2021-06-22 香港理工大学深圳研究院 Recombinant plasmid, construction method thereof, recombinant image system and application
WO2022194255A1 (en) * 2021-03-19 2022-09-22 Shanghai Junshi Biosciences Co., Ltd. Method of treating urothelial carcinoma
WO2022245692A1 (en) * 2021-05-19 2022-11-24 Merck Sharp & Dohme Llc Treatment of cancer patients with setd2 biomarker alteration with a pd-1 antagonist
WO2023049859A1 (en) * 2021-09-24 2023-03-30 The Regents Of The University Of California Methods to predict the efficacy of neoadjuvant anti-pd-1 therapy in resectable oral-cavity squamous cell carcinoma and target post-surgical relapses
CN113981080A (en) * 2021-10-15 2022-01-28 复旦大学附属肿瘤医院 Method for generating and analyzing prediction index of platinum treatment sensitivity of advanced triple-negative breast cancer
WO2023086951A1 (en) * 2021-11-12 2023-05-19 Foundation Medicine, Inc. Circulating tumor dna fraction and uses thereof
CN114213542B (en) * 2021-12-24 2023-06-23 郑州大学第三附属医院(河南省妇幼保健院) CPS-I antibodies and uses thereof
WO2023209035A1 (en) * 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Methods and systems for predicting cancer therapy response
CN114736967A (en) * 2022-05-07 2022-07-12 北京大学肿瘤医院 Markers and methods for predicting primary drug resistance of immune checkpoint inhibitor therapy
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
CN115449555B (en) * 2022-10-26 2023-10-13 山东大学 Application of ADGRA2 as biomarker for breast cancer chemotherapy efficacy and prognosis evaluation
CN116449009A (en) * 2023-01-30 2023-07-18 上海秤信生物科技有限公司 Autoantibody marker for predicting immune neoadjuvant therapeutic effect of patients with lung cancer in third stage

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
DK0590058T3 (en) 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998016249A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
ATE458008T1 (en) 1998-12-23 2010-03-15 Pfizer HUMAN MONOCLONAL ANTIBODIES AGAINST CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
BRPI0017590B8 (en) 1999-06-25 2021-05-25 Genentech Inc maytansinoid conjugate - anti-erbb antibody, and pharmaceutical formulation
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
KR20020047132A (en) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 Human ctla-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
JP2006500921A (en) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー Humanized antibody against human 4-1BB
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
DE602004024041D1 (en) 2003-03-05 2009-12-24 Halozyme Inc SOLUBLE HYALURONIDASE GLYCOPROTEIN (SHASEGP), METHOD OF ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
EP1639013B1 (en) 2003-07-02 2012-09-12 Innate Pharma Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
PL1836225T3 (en) 2005-01-06 2012-05-31 Novo Nordisk As Kir-binding agents and methods of use thereof
DK2343320T3 (en) 2005-03-25 2018-01-29 Gitr Inc ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN105037549B (en) 2007-01-11 2018-09-28 诺和诺德公司 Anti-KIR antibodies, preparation and its application
JP2008278814A (en) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk Release of immunoregulation by agonistic anti-human gitr antibody, and application thereof
PL2170959T3 (en) 2007-06-18 2014-03-31 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PT2175884T (en) 2007-07-12 2016-09-21 Gitr Inc Combination therapies employing gitr binding molecules
JP5535074B2 (en) 2007-10-01 2014-07-02 ブリストル−マイヤーズ スクウィブ カンパニー Human antibodies that bind to mesothelin and uses thereof
US20110085970A1 (en) 2007-11-30 2011-04-14 Terrett Jonathan A Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
PL2376535T3 (en) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (en) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 Anti-gitr antibodies
SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012071411A2 (en) 2010-11-22 2012-05-31 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
WO2012122444A1 (en) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
SG195082A1 (en) 2011-05-25 2013-12-30 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
EP2776032B1 (en) 2011-11-09 2018-10-17 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
DK2785375T3 (en) 2011-11-28 2020-10-12 Merck Patent Gmbh ANTI-PD-L1 ANTIBODIES AND USES THEREOF
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
KR101566539B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th2 cell and use thereof
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
PL2904011T3 (en) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
MX2016003292A (en) 2013-09-13 2016-06-24 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics.
ES2728578T3 (en) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CA2932767A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
SI3081576T1 (en) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PE20161344A1 (en) * 2014-01-02 2016-12-23 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
SG11201609721WA (en) 2014-05-28 2016-12-29 Agenus Inc Anti-gitr antibodies and methods of use thereof
KR20170080697A (en) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 Checkpoint blockade and microsatellite instability
MA40737A (en) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
EP3237446B1 (en) 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
KR20170135860A (en) 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of using them
KR20170140316A (en) * 2015-04-28 2017-12-20 브리스톨-마이어스 스큅 컴퍼니 Treatment of PD-L1-positive melanoma with anti-PD-1 antibody
CN107849144B (en) 2015-05-29 2021-09-17 艾吉纳斯公司 anti-CTLA-4 antibodies and methods of use thereof
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
PL3328419T3 (en) 2015-07-30 2021-12-27 Macrogenics, Inc. Pd-1-binding molecules and methods of use thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
RU2729830C2 (en) 2015-08-11 2020-08-12 Уси Байолоджикс (Кайман) Инк. Novel anti-pd-1 antibodies
AR105654A1 (en) 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
AR107781A1 (en) 2015-12-14 2018-06-06 Macrogenics Inc BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
WO2017123557A1 (en) 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
EP3523451A1 (en) * 2016-10-06 2019-08-14 Genentech, Inc. Therapeutic and diagnostic methods for cancer

Also Published As

Publication number Publication date
BR112019019795A2 (en) 2020-04-22
MX2019010958A (en) 2019-10-17
MA50056A (en) 2020-02-05
JP2020512982A (en) 2020-04-30
US20230295737A1 (en) 2023-09-21
JP7458188B2 (en) 2024-03-29
SG11201908396PA (en) 2019-10-30
IL269026A (en) 2019-10-31
AU2018243754A1 (en) 2019-10-17
EP3601355A1 (en) 2020-02-05
CA3058175A1 (en) 2018-10-04
KR20190133213A (en) 2019-12-02
US20210101980A1 (en) 2021-04-08
WO2018183928A1 (en) 2018-10-04
CN110494450A (en) 2019-11-22

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
IL275663A (en) Methods of treating cancer
HK1258098A1 (en) Methods of treating cancer
HK1251408A1 (en) Methods of treating cancer
ZA201804227B (en) Methods of treating cancer
ZA202006746B (en) Methods of treatment
IL262342A (en) Methods of treating cancer
IL264443A (en) Methods of treating prostate cancer
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL263508A (en) Methods of treating pancreatic cancer
ZA201908539B (en) Method of treatment of cancer
SG11202010793UA (en) Methods of treating cancer
IL263835A (en) Exosome-guided treatment of cancer
IL271934A (en) Methods of treating tumor metastasis
IL274314A (en) Methods of treating a tumor
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL277981A (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
IL272379A (en) Methods of treating cancer by inhibiting setd2
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL274748A (en) Improved treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy